BCLI:NSD-Brainstorm Cell Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.41

Change

-0.02 (-0.58)%

Market Cap

USD 0.13B

Volume

0.09M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+6.68 (+1.54%)

USD175.20B 51.28 41.56
BNTX BioNTech SE

-2.09 (-0.61%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

+0.11 (+0.02%)

USD69.19B 11.68 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.53 (-0.82%)

USD48.20B 24.50 16.63
BGNE BeiGene Ltd

-0.33 (-0.08%)

USD41.72B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+4.15 (+2.51%)

USD30.02B 51.49 39.11
GMAB Genmab A/S

-0.22 (-0.50%)

USD28.07B 71.33 8.17
RPRX Royalty Pharma plc

-0.34 (-0.93%)

USD22.24B 29.66 12.50
ALNY Alnylam Pharmaceuticals Inc

-1.94 (-1.05%)

USD21.89B N/A N/A

ETFs Containing BCLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.64% 36% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.64% 36% F 17% F
Trailing 12 Months  
Capital Gain -75.61% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.61% 3% F 2% F
Trailing 5 Years  
Capital Gain 39.75% 65% D 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.75% 64% D 47% F
Average Annual (5 Year Horizon)  
Capital Gain 30.88% 63% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.88% 63% D 75% C
Risk Return Profile  
Volatility (Standard Deviation) 83.24% 37% F 21% F
Risk Adjusted Return 37.10% 63% D 53% F
Market Capitalization 0.13B 25% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.09 45% F 35% F
Price / Cash Flow Ratio -3.68 29% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -146.19% 15% F 15% F
Return on Invested Capital -272.66% 4% F 2% F
Return on Assets -59.04% 8% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.14 40% F 26% F
Short Percent 3.24% 67% D+ 47% F
Beta -0.01 94% A 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector